Abstract
Four new derivatives of hydrocortisone, each containing in common a methyl grouping at the 16a-carbon position of the steroid molecule, have been synthesized and are being studied in human subjects. The compounds are 16a-methyl 9a-fluoroprednisolone (MK-125: hexadecadrol), 16a-methyl 9a-fluorohydrocortisone (MK-126), 16a-methylprednisolone (MK-110), and 16a-methylhydrocortisone (MK-117). Biologic tests in animals have indicated that these analogues exhibit, in varying degrees, striking alterations of several physiologic properties, including enhanced anti-inflammatory activity unassociated with corresponding disturbance of electrolyte metabolism.
In the present study preliminary observations of the effects of the four new compounds were made in patients with rheumatoid arthritis. Clinical estimates of the antirheumatic potencies of the compounds, as compared with prednisolone, were accomplished by determining the milligram dosages required to maintain similar degrees of improvement of active rheumatoid manifestations. The approximate antirheumatic potencies of the compounds, on an average, were gauged as follows: for 16a-methyl 9a-fluoroprednisolone, about seven times greater than prednisolone; for 16a-methyl 9a-fluorohydrocortisone, about three times greater; for 16a-methylprednisolone, approximately one-third greater; and for 16a-methylhydrocortisone, about 70 per cent that of prednisolone. In the dosage used, none of the compounds promoted discernible salt and water retention.
These observations would indicate that 16a-methyl 9a-fluoroprednisolone (hexadecadrol) possesses greater anti-inflammatory potency per milligram than any steroid yet produced. The therapeutic efficiency of the compound on longterm administration is being studied.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BOLAND E. W. Experiences with 9-alpha-fluorohydrocortisone acetate in rheumatoid arthritis. Ann N Y Acad Sci. 1955 May 27;61(2):591–599. [PubMed] [Google Scholar]
- BOLLET A. J., BLACK R., BUNIM J. J. Major undesirable side-effects resulting from prednisolone and prednisone. J Am Med Assoc. 1955 Jun 11;158(6):459–463. doi: 10.1001/jama.1955.02960060017005. [DOI] [PubMed] [Google Scholar]
- BUNIM J. J., BLACK R. L., BOLLET A. J., PECHET M. M. Metabolic effects of metacortandralone and metacortandracin. Ann N Y Acad Sci. 1955 May 27;61(2):358–368. doi: 10.1111/j.1749-6632.1955.tb42485.x. [DOI] [PubMed] [Google Scholar]
- BUNIM J. J., PECHET M. M., BOLLET A. J. Studies on metacortandralone and metacortandracin in rheumatoid arthritis; antirheumatic potency, metabolic effects, and hormonal properties. J Am Med Assoc. 1955 Jan 22;157(4):311–318. doi: 10.1001/jama.1955.02950210007003. [DOI] [PubMed] [Google Scholar]